Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956699 | 0.94 | KMT2A (0.51) | CA1CA2ACHEKMT2AMEN1 | |
| SCHEMBL13168132 | 0.91 | CA1 (0.48) | CA1CA2ACHEKMT2AMEN1 | |
| SCHEMBL5457149 | 0.90 | CA1 (0.48) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL5460476 | 0.83 | TAOK1 (0.50) | KMT2AMEN1ALDH1A1GAATAS1R3 | |
| SCHEMBL1591232 | 0.83 | CA1 (0.48) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL1590831 | 0.83 | CA1 (0.48) | CA1CA2ACHEALDH1A1GAA | |
| SCHEMBL5956772 | 0.83 | KMT2A (0.55) | CA1CA2ACHEKMT2AMEN1 | |
| SCHEMBL5956576 | 0.83 | KMT2A (0.55) | CA1CA2ACHEKMT2AMEN1 | |
| SCHEMBL5956658 | 0.83 | ALDH1A1 (0.44) | CA1CA2ACHEMAPTALDH1A1 | |
| SCHEMBL5956478 | 0.83 | KMT2A (0.55) | CA1CA2ACHEKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297110-B1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | MERCK SHARP & DOHME (NL) | 2015-05-20 | — | — | EP | disclosed |
| EP-2297110-B1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | MERCK SHARP & DOHME (NL) | 2015-05-20 | — | — | EP | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| EP-2417101-B1 | INDANE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-23 | — | — | EP | disclosed |
| EP-2417101-B1 | INDANE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-23 | — | — | EP | disclosed |
| US-8536214-B2 | Indane derivatives as AMPA receptor modulators | N.V. ORGANON (NL) | 2013-09-17 | — | — | US | disclosed |
| US-8536214-B2 | Indane derivatives as AMPA receptor modulators | N.V. ORGANON (NL) | 2013-09-17 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2011-04-21 | — | — | US | disclosed |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2011-04-21 | — | — | US | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009147167-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | CA1 924/4885CA2 1577/4885ACHE 78/4885 |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | GRIK5, GRIN3A, GRIK2 | CA1 982/4885CA2 1683/4885ACHE 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.